Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant V940 (mRNA-4157) plus pembrolizumab versus placebo plus pembrolizumab in high-risk resected melanoma
MOH_2023-07-31_012831Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing V940 plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Melanoma recurrence prevention efficacy. Started Jun 2023; status: completed.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2023-07-31_012831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-31_012831.